Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.56 |
| ▸ | GAA | P10253 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31335674 | 0.92 | GAA (0.54) | KDM4EGAAPOLBKMT2AHSD17B10 | |
| SCHEMBL6582728 | 0.89 | KDM4E (0.67) | KDM4EGAAPOLBKMT2AHSD17B10 | |
| SCHEMBL11065578 | 0.88 | KDM4E (0.52) | KDM4EGAAPOLBKMT2AHSD17B10 | |
| SCHEMBL3972997 | 0.86 | KDM4E (0.63) | KDM4EGAAPOLBKMT2AHSD17B10 | |
| SCHEMBL7466908 | 0.85 | KDM4E (0.68) | KDM4EGAAPOLBKMT2AHSD17B10 | |
| SCHEMBL28420508 | 0.85 | KDM4E (0.53) | KDM4EGAAPOLBHSD17B10USP2 | |
| SCHEMBL24329339 | 0.83 | GAA (0.50) | KDM4EGAAPOLBKMT2AHSD17B10 | |
| SCHEMBL3899027 | 0.83 | KDM4E (0.77) | KDM4EGAAPOLBKMT2AHSD17B10 | |
| SCHEMBL1918973 | 0.83 | GAA (0.50) | KDM4EGAAPOLBKMT2AHSD17B10 | |
| SCHEMBL11385067 | 0.83 | GAA (0.63) | KDM4EGAAPOLBKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039203-A1 | Process for the preparation of 1,5-disubstituted-3-amino-1,2,4,-triazoles and substituted aminoguanidines as intermediate compounds | SANOFI-SYNTHELABO (FR) | 2004-02-26 | — | — | US | claimed |
| EP-1337519-A1 | PROCESS FOR THE PREPARATION OF 1,5-DISUBSTITUATED-3-AMINO-1,2,4-TRIAZOLES AND SUBSTITUTED AMINOGUANIDINES AS INTERMEDIATE COMPOUNDS | SANOFI-SYNTHELABO (FR) | 2003-08-27 | — | — | EP | claimed |
| WO-2002034729-A1 | PROCESS FOR THE PREPARATION OF 1,5-DISUBSTITUTED-3-AMINO-1,2,4-TRIAZOLES AND SUBSTITUTED AMINOGUANIDINES AS INTERMEDIATE COMPOUNDS | SANOFI-SYNTHELABO (FR) | 2002-05-02 | — | — | WO | claimed |
| CN-111196816-B | Seven-membered ring compound and application thereof in preventing and treating diabetes and metabolic syndrome | 中国科学院上海药物研究所 | 2022-11-04 | — | — | CN | disclosed |
| CN-111196816-A | Seven-membered ring compound and application thereof in preventing and treating diabetes and metabolic syndrome | 中国科学院上海药物研究所 | 2020-05-26 | — | — | CN | disclosed |
| US-20040039203-A1 | Process for the preparation of 1,5-disubstituted-3-amino-1,2,4,-triazoles and substituted aminoguanidines as intermediate compounds | SANOFI-SYNTHELABO (FR) | 2004-02-26 | — | — | US | disclosed |
| EP-1337519-A1 | PROCESS FOR THE PREPARATION OF 1,5-DISUBSTITUATED-3-AMINO-1,2,4-TRIAZOLES AND SUBSTITUTED AMINOGUANIDINES AS INTERMEDIATE COMPOUNDS | SANOFI-SYNTHELABO (FR) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002034729-A1 | PROCESS FOR THE PREPARATION OF 1,5-DISUBSTITUTED-3-AMINO-1,2,4-TRIAZOLES AND SUBSTITUTED AMINOGUANIDINES AS INTERMEDIATE COMPOUNDS | SANOFI-SYNTHELABO (FR) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039203-A1 | Process for the preparation of 1,5-disubstituted-3-amino-1,2,4,-triazoles and substituted aminoguanidines as intermediate compounds | PRMT1, AP3D1, IL4I1 | KDM4E 2201/4885GAA 3603/4885POLB 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.